Cabotegravir with rilpivirine for treating HIV-1 (TA757)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 5 January 2022
HIV testing: increasing uptake among people who may have undiagnosed HIV (NG60)Product type:GuidanceProgramme:NICE guidelinePublished: 1 December 2016
Deep dermal injection of non-absorbable gel polymer for HIV-related lipoatrophy (IPG439)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 23 January 2013
Cabotegravir for preventing HIV-1 in adults and young people [ID6255]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 21 August 2025
Cabotegravir with rilpivirine for the oral treatment of HIV-1 [ID3731]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Fostemsavir for treating adults with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2726]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ibalizumab for treating adults infected with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2720]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Darunavir plus cobicistat fixed dose combination for paediatric human immunodeficiency virus 1 infection [TSID10722]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Emtricitabine/tenofovir alafenamide for human immunodeficiency virus type-1 infection [TSID10723]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Lenacapavir for treating multidrug resistant HIV-1 [ID6196]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Spinal Cord Stimulation Effective for HIV NeuropathyStatus:Topic selectionProgramme:Interventional procedures guidanceExpected publication date: TBC
Lenacapavir for preventing HIV-1 in people aged 16 years or older ID6495Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Doravirine-islatravir for previously untreated HIV-1 infection [TSID12172]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Doravirine–islatravir for treating HIV-1 in people with virological suppression on bictegravir, emtricitabine and tenofovir alafenamide combination treatment [TSID12171]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Doravirine–islatravir for treating HIV-1 in people with virological suppression on antiretroviral therapy [TSID12173]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC